Almonertinib (Standard)
Product Sizes
100 mg
£ POA
HY-112823R-100MG
50 mg
£ POA
HY-112823R-50MG
10 mg
£ POA
HY-112823R-10MG
1 mg
£ POA
HY-112823R-1MG
25 mg
£ POA
HY-112823R-25MG
5 mg
£ POA
HY-112823R-5MG
About this Product
- SKU:
- HY-112823R
- Additional Names:
- HS-10296 (Standard)
- CAS Number:
- 1899921-05-1
- Extra Details:
- Almonertinib (Standard) is the analytical standard of Almonertinib. This product is intended for research and analytical applications. Almonertinib (HS-10296) is an orally available; irreversible; third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M; T790M/L858R and T790M/Del19 (IC50: 0.37; 0.29 and 0.21 nM; respectively); and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer[1][2].
- Molecular Weight:
- 525.64
- Purity:
- 99.97
- References:
- [1]Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76.|[2]Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38.|[3]Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0864(20)30714-0.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- 4[o]C; sealed storage; away from light and moisture
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
